Insider Buying: Pluri Inc. (NASDAQ:PLUR) Director Buys 976,139 Shares of Stock

Pluri Inc. (NASDAQ:PLUR) Director Alexandre Weinstein Manieu bought 976,139 shares of Pluri stock in a transaction that occurred on Monday, April 28th. The shares were acquired at an average cost of $4.61 per share, with a total value of $4,500,000.79. Following the acquisition, the director owned 931,246 shares of the company’s stock, valued at $4,293,044.06. The trade was a -2,174.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Pluri Price Performance

Shares of NASDAQ PLUR opened at $5.39 on Thursday. The company has a debt-to-equity ratio of 51.65, a current ratio of 4.81 and a quick ratio of 4.81. The stock has a market capitalization of $42.20 million, a price-to-earnings ratio of -0.97 and a beta of 0.79. The firm’s 50 day simple moving average is $4.79 and its 200-day simple moving average is $4.53. Pluri Inc. has a 12 month low of $3.33 and a 12 month high of $7.13.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $0.43 million for the quarter. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 2,563.29%.

Analyst Upgrades and Downgrades

PLUR has been the topic of several analyst reports. Industrial Alliance Securities set a $12.00 price target on Pluri in a research report on Monday, June 2nd. Alliance Global Partners assumed coverage on Pluri in a research note on Monday, June 2nd. They issued a “buy” rating and a $12.00 target price on the stock.

Institutional Investors Weigh In On Pluri

A hedge fund recently raised its stake in Pluri stock. Renaissance Technologies LLC lifted its holdings in Pluri Inc. (NASDAQ:PLUR) by 38.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,025 shares of the company’s stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned about 0.61% of Pluri worth $145,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.